Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pharmacokinetic and infusion-rate safety study of IVIG BT090 (Intratect) in primary immunodeficiency
2010-019249-25Phase 3Completed
- Sponsor
- Biotest AG
- Start
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of IgPro10 in Immunogenetic disorder and Congenital hypogammaglobulinemia (2 arms), sponsored by Biotest AG. Primary endpoint: Pharmacokinetic parameters of Intratect. Started May 2010; status: completed.
02
Drugs
IgPro10
03
Conditions
Immunogenetic disorderCongenital hypogammaglobulinemia
Beyond the preview
Go deeper on 2010-019249-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019249-25.